A5023825847- Fibromyalgia and Chronic Fatigue Syndrome Research
- Genetic Neurodegenerative Diseases
- Peripheral Neuropathies and Disorders
- Multiple Sclerosis Research Studies
- Childhood Cancer Survivors' Quality of Life
- Autoimmune and Inflammatory Disorders Research
- Musculoskeletal pain and rehabilitation
- Effects of Vibration on Health
- Therapeutic Uses of Natural Elements
- Biochemical Acid Research Studies
- Long-Term Effects of COVID-19
- Diet and metabolism studies
- CAR-T cell therapy research
- Heart Rate Variability and Autonomic Control
Haukeland University Hospital
2015-2024
University of Bergen
2021-2024
Ibero American University
2019
Myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is a debilitating disease of unknown etiology, with hallmark symptoms including postexertional malaise and poor recovery. Metabolic dysfunction plausible contributing factor. We hypothesized that changes in serum amino acids may disclose specific defects energy metabolism ME/CFS. Analysis 200 ME/CFS patients 102 healthy individuals showed reduction fuel oxidative via the TCA cycle, mainly female patients. Serum 3-methylhistidine,...
Background Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We previously reported pilot case series followed by small, randomized, placebo-controlled phase II study, suggesting that B-cell depletion using the monoclonal anti-CD20 antibody rituximab can yield clinical benefit in ME/CFS. Methods In this single-center, open-label, one-armed study (NCT01156909), 29 patients were included for treatment with (500 mg/m2) two infusions weeks apart,...
Objective A few earlier studies have found impaired endothelial function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The present study investigated large-vessel and small-vessel ME/CFS. Study design was a substudy of the RituxME trial, national, multicenter, randomized, double-blind, placebo-controlled phase III on effect rituximab vs. placebo ME/CFS Norway. Flow-mediated dilation (FMD) post-occlusive reactive hyperemia (PORH) measured at baseline after 18...
Previous phase 2 trials indicated benefit from B-lymphocyte depletion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).To evaluate the effect of monoclonal anti-CD20 antibody rituximab versus placebo patients with ME/CFS.Randomized, placebo-controlled, double-blind, multicenter trial. (ClinicalTrials.gov: NCT02229942).4 university hospitals and 1 general hospital Norway.151 aged 18 to 65 years who had ME/CFS according Canadian consensus criteria disease for 15 years.Treatment...
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease usually presenting after infection. Emerging evidence supports that energy metabolism affected in ME/CFS, but unifying metabolic phenotype has not been firmly established. We performed global metabolomics, lipidomics, and hormone measurements, we used exploratory data analyses to compare serum from 83 patients with ME/CFS 35 healthy controls. Some changes were common the patient group, these compatible...
Introduction: Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) present a range of symptoms including post-exertional malaise (PEM), orthostatic intolerance, and autonomic dysfunction. Dysfunction the blood vessel endothelium could be an underlying biological mechanism, resulting in inability to fine-tune regulation flow according metabolic demands tissues. The objectives study were investigate endothelial function ME/CFS patients compared healthy individuals, assess...
Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with high symptom burden, of unknown etiology, no established treatment. We observed patients long-standing ME/CFS who got cancer, and reported improvement symptoms after chemotherapy including cyclophosphamide, forming the basis for this prospective trial. Materials methods: This open-label phase II trial included 40 diagnosed by Canadian criteria. Treatment consisted 6 intravenous infusions 600-700...
Objectives In this six-year follow-up study, we used patient-reported outcome measures (PROMs) to compare values at baseline, 18 months, and follow up from the CycloME RituxME trials. Methods Based on hypothesis that ME/CFS in a subgroup of patients is variant an autoimmune disease, performed two clinical trials between 2014 2017. The trial was randomized, double-blind placebo-controlled phase III 151 patients, assessing B-cell depleting antibody rituximab. open-label II 40 using intravenous...
The etiology of myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is unknown, but involvement the immune system one proposed underlying mechanisms. Human leukocyte antigen (HLA) associations are hallmarks immune-mediated and autoimmune diseases. We have previously performed high resolution HLA genotyping detected between ME/CFS certain class I II alleles. However, complex harbors numerous genes immunological importance, there extensive linkage disequilibrium across region. In...
Introduction Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with no validated specific and sensitive biomarker, standard approved treatment. In this observational study intervention, participants used Fitbit activity tracker. The aims were to explore natural symptom variation, feasibility of continuous monitoring, compare data patient reported outcome measures (PROMs). Materials methods pilot study, 27 patients mild severe ME/CFS, mean age 42.3 years, the Charge 3...